Clinical Trials at Broadlawns Medical Center

As of July 2026, 48 paid clinical trials are recruiting at Broadlawns Medical Center, located at 1801 HICKMAN RD, DES MOINES, IA 50314-1505, phone (515) 282-2200 in Des Moines, Iowa. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

48 clinical trials at Broadlawns Medical Center

·Clear filters·↓ Download CSV

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

for Locally Advanced Adrenal Cortical Carcinoma

Drug: Cabozantinib

71 locations incl. La Jolla

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 12+

Code: NCT06900595·Phase 2·Recruiting

Apply to this trial

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

for Astrocytoma, IDH-Mutant, Grade 3

Drug: Vorasidenib

82 locations incl. Duarte

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 12+

Code: NCT07215910·Phase 3·Recruiting

Apply to this trial

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

for Recurrent Head and Neck Squamous Cell Carcinoma

178 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 79

Code: NCT04671667·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

for Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

100 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07195734·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

for Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Drug: Nivolumab

55 locations incl. Los Angeles

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04609046·Phase 1·Recruiting

Apply to this trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

for Metastatic Nasopharyngeal Carcinoma

Drug: Relatlimab

83 locations incl. Dublin

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06029270·Phase 2·Recruiting

Apply to this trial

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

for Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

140 locations incl. Tucson

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT03493425·Phase 2·Recruiting

Apply to this trial

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Ribociclib

61 locations incl. Jonesboro

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07391774·Phase 3·Recruiting

Apply to this trial